- Day One Reports First Quarter 2024 Financial Results and Corporate Progress
- Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
- Day One Announces Two New Appointments to Board of Directors
- Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
- Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
- Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
More ▼
Key statistics
As of last trade Day One Biopharmaceuticals Inc (DAWN:NSQ) traded at 16.50, -8.69% below its 52-week high of 18.07, set on May 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.76 |
---|---|
High | 17.04 |
Low | 16.42 |
Bid | 16.46 |
Offer | 16.51 |
Previous close | 17.08 |
Average volume | 1.93m |
---|---|
Shares outstanding | 87.38m |
Free float | 70.16m |
P/E (TTM) | -- |
Market cap | 1.49bn USD |
EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of May 08 2024 15:03 BST.
More ▼